Reuters logo
BRIEF-Genmab announces U.S. FDA approval of Darzalex (Daratumumab) for relapsed multiple myeloma
2016年11月21日 / 晚上8点57分 / 1 年内

BRIEF-Genmab announces U.S. FDA approval of Darzalex (Daratumumab) for relapsed multiple myeloma

Nov 21 (Reuters) - Genmab A/S :

* Genmab announces U.S. FDA approval of Darzalex (Daratumumab) for relapsed multiple myeloma and updates financial guidance

* Genmab will receive milestone payments totaling $65 million from Janssen

* Genmab says anticipate that 2016 operating expenses will remain in range of DKK 800 - 850 million

* We expect 2016 revenue to be in range of DKK 1,650 million - 1,700 million, an increase of DKK 450 million compared to previous guidance

* Genmab says now expect operating income for 2016 to be approximately DKK 825 - 875 million

* Expect FY 2016 Darzalex royalties to remain in range of DKK 400 million - 450 million Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below